Expression of ribophorine II is a promising prognostic factor in human gastric adenocarcinoma

International Journal of Oncology

Volumn 50, Issue 2, 2017, Pages 448-456

  Fujimoto, Daisuke ^a   Goi, Takanori ^a   Hirono, Yasuo ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

CRISPR Cas9; Gastric adenocarcinoma; Immunohistochemistry; Prognostic factor; Ribophorine II

Indexed keywords

MEMBRANE PROTEIN; PROTEIN P53; RIBOPHORINE II; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; GLYCOSYLTRANSFERASE; PROTEASOME; RPN2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL INVASION; CONTROLLED STUDY; DEPTH OF WALL INVASION; DISEASE FREE SURVIVAL; ENOME EDITING; FEMALE; GASTRIC ADENOCARCINOMA CELL; GENE INACTIVATION; GENERAL ASPECTS OF DISEASE; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RPN2 GENE; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; ADENOCARCINOMA; BIOSYNTHESIS; GENE SILENCING; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEXOSYLTRANSFERASES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 85013040142     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3822     Document Type: Article

References (28)

1. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA and Hamilton SM: Gastric adenocarcinoma: Review and considerations for future directions. Ann Surg 241: 27-39, 2005.
2. Nissan A, Garofalo A and Esquivel J: Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for gastric adenocarcinoma: Why haven't we reached the promised land? J Surg Oncol 102: 359-360, 2010.
3. Glehen O, Mohamed F and Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5: 219-228, 2004.
4. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
5. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
6. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
7. Takei Y, Takigahira M, Mihara K, Tarumi Y and Yanagihara K: The metastasis-associated microRNA MIR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res 71: 1442-1453, 2011.
8. Motoyama K, Inoue H, Mimori K, Tanaka F, Kojima K, Uetake H, Sugihara K and Mori M: Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol 36: 1089-1095, 2010.
9. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al.: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol 11: 136-146, 2010.
10. Zhang Z, Liu S, Shi R and Zhao G: MIR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. Cancer Genet 204: 486-491, 2011.
11. Okugawa Y, Inoue Y, Tanaka K, Kawamura M, Saigusa S, Toiyama Y, Ohi M, Uchida K, Mohri Y and Kusunoki M: Smad interacting protein 1 (SIP1) is associated with peritoneal carcinomatosis in intestinal type gastric cancer. Clin Exp Metastasis 30: 417-429, 2013.
12. Takahashi RU, Takeshita F, Honma K, Ono M, Kato K and Ochiya T: Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β. Sci Rep 3: 2474, 2013.
13. Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 14: 113-123, 2011.
14. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
15. Nguyen DX, Bos PD and Massagué J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284, 2009.
16. Löffler C, Rao VV and Hansmann I: Mapping of the ribophorin II (RPN II) gene to human chromosome 20q12-q13.1 by in-situ hybridization. Hum Genet 87: 221-222, 1991.
17. Testa JR, Kinnealey A, Rowley JD, Golde DW and Potter D: Deletion of the long arm of chromosome 20 [del(20)(q11)] in myeloid disorders. Blood 52: 868-877, 1978.
18. Kelleher DJ, Kreibich G and Gilmore R: Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kd protein. Cell 69: 55-65, 1992.
19. Kelleher DJ and Gilmore R: An evolving view of the eukaryotic oligosaccharyltransferase. Glycobiology 16: 47R-62R, 2006.
20. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K and Ochiya T: RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 14: 939-948, 2008.
21. Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, Mou H and Lu W: MIR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget 7: 24510-24526, 2016.
22. Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, Chen M, Wang X, Kang Y, Zhou Y, et al.: Targeting the MIR-221-222/PUMA/BAK/ BAX pathway abrogates dexamethasone resistance in multiple myeloma. Cancer Res 75: 4384-4397, 2015.
23. Ma J, Fang B, Zeng F, Ma C, Pang H, Cheng L, Shi Y, Wang H, Yin B, Xia J, et al.: Down-regulation of MIR-223 reverses epithelial- mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget 6: 1740-1749, 2015.
24. Yukimoto K, Nakata B, Muguruma K, Yashiro M, Ohira M, Ishikawa T, Hino M and Hirakawa K: Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastric cancer cells with or without p53 mutation. Int J Oncol 19: 373-378, 2001.
25. Endo F, Nishizuka SS, Kume K, Ishida K, Katagiri H, Ishida K, Sato K, Iwaya T, Koeda K and Wakabayashi G: A compensatory role of NF-κB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines. PLoS One 9: e90155, 2014.
26. Fujita Y, Yagishita S, Takeshita F, Yamamoto Y, Kuwano K and Ochiya T: Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer. Oncotarget 6: 3335-3345, 2015.
27. Boyer B, Vallés AM and Edme N: Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 60: 1091-1099, 2000.
28. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, et al.: p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208: 875-883, 2011.